Innovate Conferences

Innovate Conferences Vaccines

Innovate Immunology 2017
Innovate Home

Welcome Note

Welcome to the keynote forum, plenary speakers, delegates, collaboration, exhibitors, sponsors, the press, and other participants to the International summit on Vaccines and Immunology . It’s an exciting time for attending “Innovate Immunology 2017” as we continue to grow and adapt, remaining always adaptable, motivated and responsive for “Accelerating Next-Generation Vaccines for Global Health”. Our organization is confronting a time of many changes and we’re meeting these changes during a time of larger nation-wide and global change. The world of vaccination is an exciting area in which to work on immunization, and we’ll continue to meet and bring inspired people together in forums like this, to ensure our Innovate conferences remains at the cutting edge.

We would like to give you an idea of what you can expect and what we hope to achieve. Academic researchers, public health clinicians, veterinarians, vaccine policy makers, Vaccine Research Development and manufacturers, Vaccine Business, Immunological Research and Vaccine Value Chain community, People focused on Immunoinformatics and Vaccines and Vaccine Informatics with the following profession areas: Innovators, Disruptors, and Influencers can exchange ideas and collaborate.

We’re transforming the way we operate to continuously improve our ability to meet with current and potential scientists, make a splash with new vaccines developments, and receive name recognition at this event. Our employees and partners have continued to meet the challenges of our field and to excel despite setbacks. We should all be very proud of where we are today and excited about where we are headed.

Before we close, We would like to thank each of you for attending our conference and bringing your expertise to our gathering. You, as organization leaders, have the vision, the knowledge and the experience to help us pave our way into the future. You are truly our greatest asset today and tomorrow, and we could not accomplish what we do without your support and leadership. Throughout this conference, We ask you to stay engaged, keep us proactive and help us shape the future of vaccines science and research. Our personal respect and thanks go out to all of you.

Innovate Immunology 2017
Operating Committee
Innovate Conferences

About Innovate Immunology 2017

The Innovate Immunology 2017 is a unique event. It focuses on the field of Vaccine Business, Immunology Research & Development. In recognition of the global spread of Vaccines for Emerging, Re-Emerging, Infectious and Rare Diseases, the conference is held in a different part of the world every year. The presentations are international in scope and include the latest in incident response and prevention, vulnerability analysis, and related aspects of Immunology. Additionally, these events serve as the foundation for the improvement of worldwide via the sharing of viewpoints, ideas, and information on vaccination immunization and science.

Why To Attend?

  • To Meet World’s High-Level Scientific verbalizers for industry perspective.
  • Learn from leading non-profit organizations and regime bodies.
  • Meet the people in your field - can lead to incipient opportunities for collaborative efforts, Incipient Tips.
  • Present your latest research in front of the world
  • To know the current state of research and the challenges to future revelation
  • Networking.
  • Face to Face Interactions with your field experts.
  • Business-Business Meetings.
  • Scientific Sessions, Keynote Forum, Exhibition, Workshops, Symposia, Poster Presentations, Video Presentations and Student Guidance.
  • Meet with international colleagues, make incipient friends.

Who Should Attend?

You do not need to be a member of Innovate Immunology 2017 to attend the conference. Responsibility for coordinating the wide range of disciplines in the field of vaccination and therapeutics should attend.

  • Vaccinology/Immunology Researchers
  • Associations and Societies for collaboration and sponsorship.
  • Manufacturing Medical Devices Companies for Exhibition.
  • Policy and decision makers with disciplines in the field of vaccination and therapeutics
  • Vaccine stakeholders including academic researchers, public health clinicians, veterinarians.
  • Vaccine policy makers and manufacturers can exchange ideas and collaboration.
  • Meet colleagues from around the world and exchange ideas and bits of advice.

Innovate conferences are attracting participants representing more than 53 countries around the world.

Innovate Executive Program:

If you are a  potential scientist who is interested in making a splash with new vaccines developments to exchange ideas, may well be the event for you. It is a 2-day event in parallel to the conference, tailored around Vaccinology/Immunology and its advances- a unique opportunity to meet like-minded and share the insights of the world's foremost specialists in Vaccines & Vaccination.

Conference Benefits:

Innovate Immunology 2017 conferences are comprised of Scientific Sessions, Keynote Forum, Exhibition, Workshops, Symposia, Poster Presentations, Video Presentations, Networking, Face to Face Discussions, Business-Business Meetings, Certifications where the most recent developments will be discussed and shared.

Conference Topics

Global Market Analysis

Currently there is a rapid magnification in the Immunology and Vaccines Ecumenical Market and the major market share holds F. Hoffmann-La Roche Ltd, Abbott Laboratories, Shanghai Kehua Bio-engineering Co., Ltd, Transasia Bio-Medicals Ltd, Span Diagnostics Ltd, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc in the immunology segment and Pfizer, Novartis, Sanofi, and GlaxoSmithKline in vaccines upt0 raise in 74-92% of the ecumenical market by 2022

Overview of the Global Immunology Market:

The immunology market for infectious diseases comprises of diagnosis and treatment of such infections predicated on the antibody and antigen reaction. Innovations and developments in the immunological technologies are very constrained but fixated on exploring the applications in other infections. The major infections where immunological products used are hepatitis, rotavirus infections, and other viral and bacterial infections.

Currently sundry established companies in diagnostic and healthcare segment catering varied range of products such as reagents, test kits and instruments in this market out of which companies such as F. Hoffmann-La Roche Ltd, Abbott Laboratories, Shanghai Kehua Bio-engineering Co., Ltd, Transasia Bio-Medicals Ltd, Span Diagnostics Ltd, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc are leading contributors in reagents and test kits, on the other hand Siemens Healthcare and PerkinElmer, Inc. are major companies in Instruments segment.

Albeit the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience perpetuated magnification, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual magnification rate of 2.71%.

Top Pharma Companies in Immunology Sales - AbbVie, Johnson & Johnson, Pfizer, Amgen, Merck & Co., Astellas, Roche, Novartis, Bristol-Myers Squibb. Global Immunology Treatment Market Will Exceed $74 Billion by 2022

The global vaccine market has been established as one of the fastest-growing segments of the medical and healthcare industry. The fact that vaccination has saved millions of lives including adults, children, and animals, providing them a better and healthier life, is the prime reason behind the growth of this market.

The global vaccine market is broadly analyzed on the basis of product types and antigens. Based on types of products, the global vaccine market is classified into pediatrics and adult vaccine markets, while by antigen, the market is categorized into Hepatitis A and B, human papillomavirus, meningococcal, influenza, pneumococcal, combination vaccines, and others.

This research report on the global vaccine market provides a detailed assessment of the previous, existing as well as the future performance of the global vaccine markets. Furthermore, the study elaborates upon the competitive landscape of the global market for vaccines by offering the business outlook and future prospects of the major participants of the market.

Overview of the Global Vaccine Market:

Once considered as a commodity market, the global market for vaccines is now among the fastest developing markets for the pharma industry. Witnessing massive growth in recent times and outpacing many of the conventional businesses operational in the pharmaceutical market, the vaccine industry has captured almost 3% of the overall pharmaceutical industry. Continual product innovation and positive response from diverse demographics are fueling market growth to great extents.

As vaccination has a low risk of serious side effects, the uptake of vaccines has been rising with increasing awareness among patients, medical and healthcare professional, and the general populace.  Apart from this, stringent recommendations for immunization from many governments across the globe against various diseases and the rise in the demand for adult vaccines are also adding to the growth of this market.

On the other hand, the strict procedure for regulatory approvals and the high cost associated with research to discover a new vaccine and its development is likely to influence market growth in a negative manner during the period from 2011 to 2016.

Additionally, shipping, storing, and handling of vaccines are some of the major challenges the producers and distributors functioning in the global vaccine market face on a regular basis. For over 90% of all vaccines, producers have to depend on cold chain logistics to avoid accidental exposure to temperatures above the recommended range in order to avoid loss of potency and efficiency of the vaccine as well as to manage the high maintenance costs. These factors are also projected to limit the growth of the global vaccine market.

Companies Mentioned In the Research Report:

The global market for vaccines is highly concentrated and the top four market players, namely Pfizer, Novartis, Sanofi, and GlaxoSmithKline, collectively control 74% of the global market. Other prominent players in the global vaccine market are Emergent Biosolutions, Inc. Boehringer Ingelheim, Merck & Co., Inc., Medimmune LLC., Bavarian Nordic, CSL Ltd., and Zoetis, Inc.

Major geographies analyzed under this research report are:

  • Europe
  • North America
  • Asia-Pacific
  • Rest of the World

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years
  • Key highlights of this report
  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends

Please Select Valid Input
Please Enter Valid Input
Please Enter Valid Country Name
Please Enter Valid Email
Please Enter Valid Phone Number
Please Select Valid Input
Please select valid file with extesion .doc or .docx
Personal Information
Invalid Selection
Invalid Input
Invalid Input
Invalid Input
Invalid Input
Invalid Input
Invalid Selection
Billing Information
Registration On/Before Feb 27th 2017 - Academia On/Before Feb 27th 2017 - Business On/Before March 27th 2017 - Academia On/Before March 27th 2017 - Business On/Before April 27th 2017 - Academia On/Before April 27th 2017 - Business
Speaker Registration
Package A (Registration + 2 Nights)
Package B (Registration + 3 Nights)
Poster Presentation
Video Presentation
Accompanying Person(s)
Additional Accommodation For Night(s)
Group Participation Academia Business Academia Business Academia Business
5 Participants
10 Participants
15 Participants
Registration On/Before Feb 27th 2017 On/Before March 27th 2017 On/Before April 27th 2017
Product Category Business Business Business
Royal Package
Others (USD)


Category Price
**Taxes Applicable**

Giulio Tarro,
Naples University,


Giulio Tarro graduated from Medicine School, Naples University (1962). Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. Oncological Virology Professor, Naples University (1972-1985). Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus, 2006 -. Since 2007 Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). President Foundation de Beaumont Bonelli for Cancer Research. His basic researches have been concerned with antigens induced early during the replication cycle of human herpesviruses. Another study has involved the identification, isolation and characterization of specific virus-induced tumour antigens, which were the “finger-prints” left behind in human cancer.Achievements include patents in field; discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas.

Vaccines for Oncogenic Viruses and tumor associated antigens.

Mohamed Labib Salem,
Professor of Immunology,
Director, Center of Excellence in Cancer Research (CECR),


Mohamed L. Salem (PhD, 1995) is the Professor of Immunology at Tanta University, Egypt and was Visiting Professor at Hollings Cancer Center and Department of Microbiology and Immunology, Medical University of South Carolina, USA. Dr. Salem is the Founder and Director of Center of Excellence in Cancer Research, Tanta University, Egypt and Founder and Chairman of Egyptian Association for Cancer Research. He is among the founding members of the Middle Eastern Association for Cancer Research, Canada. Dr Salem is also the Director of Delta Development Research Center which is a regional branch of Academy of Scientific Research and Technology (ASRT), Egypt; Director of the Grant, Innovation & Technology Transfer Center. Dr. Salem obtained his PhD in 1995 through a channel system between Tanta University, Egypt and Kyushu University, Japan. From 1997 -2001, he was a Postdoctoral Fellow at Kyushu University, Japan and from 2002-2010 as an Assistant Professor at Medical University of South Carolina, USA. Dr. Salem is member of several national committees including National Committee for Professorship Promotion, National Committee for the Biological Sciences, National Committee for Scientific Research Strategies, National Committee for Basic Sciences Sector at the Supreme Council of the Egyptian Universities, and National Committee of the Special Basic Science Sector at the Academy of Scientific Research and Technology, Egypt. Dr Salem won the State Incentive Award in 2004 in Biology, the State Excellence Award in 2010 in Basic Sciences from the Academy of Scientific Research and Technology, Egypt, and Tanta University Esteemed Award, Tanta University, Egypt in 2015. His h-index is 26 and published about 111 articles in peer-reviewed journals and attended more than 100 national and international workshops and conferences in Immunology. He supervised more than 55 Master and PhD students. He is a member of several editorial boards of peer-reviewed journals as well as ad hoc reviewer for more than 80 journals. He has been invited to give scientific talks in Egypt, UAE, Jordan, Saudi Arabia, USA, China and Canada. Dr Salem’s research focuses on understanding the cellular and molecular mechanisms underlying how cancer and virus escape from host immunity, in particular the rules of the immunosuppressive cells including lymphoid and myeloid lineages as well as developing effective anticancer immunotherapy strategies. His research projects have been funded by National Institute of Health, USA, Science and Technology Development Fund (STDF), Egypt, USA National Academy of Sciences, Tanta University, Egypt, private foundation and industry.

Giovanni Battista Pajno,
Associate Professor of Pediatrics,


Graduated from Medicine School Messina’s University – Italy(1982).

Pediatric Consultant Physician Allergy Unit Department of Pediatric University of Messina- Italy (1986-1995).

Honorary Consultant Physician – Upper Respiratory Medicine- Royal Brompton Hospital- London -UK.(1996-1997).

Honorary Research Fellow Department of Allergy and Respiratory Medicine: Guy’s and S. Thomas Hospital- London – UK (1997).

Reader and Consultant Pediatrician Department of Pediatrics , University of Messina- Italy (1999-2010).

Since 2010 Associate Professor of Pediatrics and Director Of Pediatric Allergy Unit University Hospital of Messina- Italy.

Since 2007 : Fellow of American Academy Allergy Asthma Immunology (AAAAI).

American College Allergy Asthma Immunology Award- International Distinguish Fellow- 2013.

Since 2015 Chair of European Academy Allergy Clinical Immunology (EAACI) Task Force on Oral Immunotherapy (OIT) for Treatment of Food Allergy.

Author of n. 10 Original Papers and Reviews on Oral Immunotherapy (OIT): The new active treatment of IgE mediated food allergy.

Oral Immunotherapy(OIT) : The new active treatment for food allergy.

Dr. Ahmed Emara,
CEO and Managing Director of ReAya Holding,
Jeddah, Saudi Arabia.


Dr. Ahmed Emara, CEO and Managing Director of ReAya Holding
Dr. Emara is a Healthcare operator & investor, enjoying a very strong international operational background & a solid track record of Private Equity Deals where he assumes the responsibility of Identifying and implementing best practices, business process assessments, mapping and process re-engineering.
He has also founded and been managing partner of several entrepreneurial ventures including Muse, a healthcare M&A and advisory firm, and Tech. Developers, an intellectual property commercialization venture.
-In addition, he has founded and has been Managing Partner of several entrepreneurial ventures including Muse, a healthcare M&A and managing-advisory firm, and Tech. Developers, a pioneer intellectual- properties-commercialization corporation. Earlier, Dr. Emara held various senior management positions in affiliations with distinguished multinational companies like Sanofi, Bayer, Abbott, & Spimaco.
Furthermore, he has held & still holds several positions of significant responsibilities:
-CEO of Jeddah BioCity, a pioneer life science venture-capital firm,
-Board Member, Exec & Finance Committ. of Arabio, first JV Biological plant in MENA
-Managing Director of ESD, a hazardous-medical-waste-management corporation
-Managing Director of BioScan, a unique cyclotron cancer-diagnostic center
-Board Director at SABA Medical, a 30 yrs old Ambulatory Healthcare group
-Managing Director & CEO of Metrek a chain of retail pharmacies and polyclinics.
-Chairman & CEO of Avrupagoz, a leading Turkish chain of ophthalmology centers.
-Managing Director & CEO of Zahrawi, Dubai-based distributor of Medical Devices.
-Chairman of Orzax, a Turkish production & marketing co. nutritional supplements.
As a "thought leader, Dr. Emara is a regular panelist and speaker on healthcare private equity & operational excellence at industry conferences.
Dr. Emara, received his Bachelor’s degree in Medicine & Surgery from Cairo University, Egypt in 1992 and earned his MBA from City University, Seattle, USA in 2001.

Matevz Leskovsek,
CEO Breathing Labs,
Slovenia, Europe.


Matevz Leskovsek, PhD, is a founder and managing director of, a company that produces human computer interfaces for breathing exercises, breathing games, and breathing entertainment. Dr. Leskovsek specializes in biofeedback, cardio-respiratory interaction, and neurology/brain research. He has led Society of Young researchers of Slovenia through fund raising and organization of an annual Mentor of the year award, that has been, among others, praised by the leading scientific journal Nature (Slovenian Scientists Reward Mentors, Nature, 09th June 2011.

DNA vaccines via electro-gene transfer delivery.

Luis Martin,
Chief Executive Officer at PREVENT,


Dr. Luis Martin is Current CEO at PREVENT previously Dr. Luis Martin worked as Chief Science Officer at Pan-Provincial Vaccine Enterprise (PREVENT), Chief Commercialization Officer at Mitomics Inc, Director, Product Development at Pan-Provincial Vaccine Enterprise (PREVENT), Managing Director and Founder at Lumar Management Consulting Inc (LMCI), Head, Research and Development at Arius Research Inc, Vice President Research and Development at Gensel Biotechnologies Inc, Director Immunobiology at Biomira, Director at Biomira Inc. Section Head at NRC Biotechnology Research Institute and Visiting Scientist at MRC Laboratory for Molecular Biology (Cambridge, UK)
Education : Dr. Luis Martin Completed Ph.D., Cell Biology at University of Waterloo During 1980 – 1984

A New Funding Paradigm for Vaccine Innovation and its Application to the Development of a Novel Vaccine for Group A Streptococcus.

Dr. Pascal Breton, Ph.D,
Président of VitamFero SAS,
University of Orléans (France).


Dr. Pascal Breton, Ph.D. serves as Chief Executive Officer of VitamFero S.A. and has been its President since January 2009. His Interest in various fields includes Biotechnology, R&D, Business Development, Drug Development, Pharma/Clinical Development, Drug Discovery and Formulation and Vaccines. Before founding and heading VitamFero, Dr. Pascal Breton worked as Global Key Account Manager Biotech at SGS Life Science Services (Belgium), Director Business Development at IDM Pharma (France and USA), Director R&D at Halisol (France) and Project Leader at UPSA (a French BMS subsidiary).
Dr. Pascal Breton holds a Ph.D. from University of Orléans (France) in 1989.

David (W) Vincent,
Validation Technologies, Inc. CEO,
VTI Global Regulatory Consultants,
VTI Pharmaceutical Technology (Shenzhen) Co. Ltd,
California Coast University,


Dr. Vincent has over thirty-one (32) years’ experience in the life science industry specializing in the Pharmaceutical, Biotechnology, and Biopharmaceutical and Medical Device industries. Dr. Vincent has degrees in industrial microbiology and mechanical engineering. He has over (27) twenty-seven years dedicated to the field of commissioning and qualification. He has expertise in many areas of Regulatory Affairs, Quality Assurance and Validation Engineering including; regulatory submission preparation, Design Review, Construction Qualification, Project Management, Utility and Process Equipment Qualification implementation. He is especially strong in the areas of Process Development and Validation as well as developing and implementing Environmental Monitoring and Cleaning Validation Programs.

Dr. Vincent has spent the last twenty (20) years providing validation and quality consultant services to various companies. During this time, Mr. Vincent has provided both project management and project execution for numerous clients national and international. He is responsible for managing and supporting many different product launches and licensing. He is the Quality Assurance Coordinator for Validation Technologies, Inc. and is responsible for implementing and maintaining VTI’s Internal Quality Programs, ISO certification and corporate training. He teaches at San Diego State University (SDSU) for their Masters of Regulatory Affairs Degree program in the Field of Validation Technology RA-776.

Dr, Vincent is responsible for supporting the regulatory submission and licensing (FDA, EU, WHO) of many facilities both nationally and internationally.

He has written many articles and presented national and international on the topics of validation and quality systems.

In 2006 because of his year’s service in the life science industry he was awarded the businessman of the year for the state of California and the recognition of outstanding meritorious services by the NRCC

He is also the co-founder and CEO for Validation Technologies, Inc. USA, VTI Global Regulatory Consultants and VTI Pharmaceutical Technology (Shenzhen) Co. Ltd.

Current regulatory trends for Vaccines.

Pierre A. MORGON PharmD LL.M MBA,
CEO MRGN Advisors - NED Theradiag, Eurocine Vaccines - Regional Partner Mérieux Développement – 20'500+ Level 1,


TITLE OF SPEECH Clinical Development of Vaccines, and the Path to Market for Prevention Solutions
Pierre A. MORGON Chief Executive Officer of MRGN Advisors and Regional Partner for Switzerland at Mérieux Développement. I'm also Non-Executive Director to the Board of Theradiag, a company focusing on in vitro diagnostics in auto-immunity, infectious diseases and allergy, as well as Non-Executive Director to the Board of Eurocine Vaccines, a company dedicated to developing nasal vaccines.
Pierre A. MORGON hold a Doctorate of Pharmacy from Lyon University, France, a Master in Business Law from the Lyon Law School and a MBA from ESSEC, France. I'm also an alumnus of INSEAD, IMD and MCE executive programs.
Pierre A. MORGON have over 29 years of experience in the global pharmaceutical and biological industry and in healthcare IT, both at the helm of operations (from business unit head to general manager and CEO) and in marketing and commercial positions (from product marketing at country level to global marketing strategy). Through these local and global positions, I have acquired direct experience with blockbuster products in diverse markets (primary care, specialty care, hospital, vaccines, and biotechnology), geographies (US, Europe, Japan, China, India, Emerging Markets) and organizations
Pierre A. MORGON have spent 2 years at ICI-Pharma, followed by 8 years at Synthelabo, then a division of L’Oreal.
Pierre A. MORGON joined Aventis Pasteur in 1998, then I had diversified experiences in operations at Yamanouchi Pharma, BMS, Drug Abuse Sciences, Schering-Plough, Bio Alliance PharmaSanofi Pasteur, Cegedim and AJ Biologics.

Clinical Development of Vaccines, and the Path to Market for Prevention Solutions.

Dr. Akanksha Rathi,
Chief Medical Director, Alyssa Healthcare,


Dr. Akanksha Rathi is a young preventive health expert and vaccinologist with an experience of over 6 years in the preventive healthcare field. Her primary areas are teaching, research and healthcare service provision. She has done her graduation (MBBS) and master's degree (MD - Community Medicine) from Maulana Azad Medical College, New Delhi. She has done an advanced course in Vaccinology from Christian Medical College, Vellore. She is currently working as the Chief Medical Director of a preventive healthcare company - Alyssa Healthcare. Since 2014, she has led the company’s strategy and organizational development function. She has played a key role in developing various preventive programs and is the in-house expert of vaccination. She has conducted various awareness camps in resident welfare associations and corporate offices about 'Adolescent & Adult Vaccinations with special focus on HPV vaccine'. She is also providing consultation services to a diabetes clinic where she focuses on diabetes prevention, diabetes management, prevention of complications and rehabilitation. Before devoting her full time to Alyssa Healthcare, she was doing senior residency in Maulana Azad Medical College. She headed regional health centers and was responsible for preserving and promoting the health of the community. She has trained hundreds of interns and postgraduate students in vaccination. Till now, she has vaccinated thousands of children and adults. She had done her thesis on immunization and writes regularly about the importance of introducing various vaccines for adolescents and adults. In a widely circulated health magazine - Double Helical, she has written 2 articles on cervical cancer vaccine & Importance of Adult Vaccinations. She also has 3 publications in peer-reviewed journals. Her most recent publication in 2016 is 'Implications of introducing IPV vaccine in national immunization schedule & strategies to combat shortages', published in Vaccine Research Journal. Her current research interests include diabetes and vaccination and she is a part of various on-going projects. To name a few: Knowledge, attitude and practices of parents about recently introduced IPV vaccine, Prevalence and pattern of Complementary and Alternative Medicine use among diabetic population & Prevalence of Autonomic neuropathy among diabetic patients. She is a member of Indian Public Health Association. She serves as a resource on various public health topics via the website of Alyssa Healthcare and the twitter account of the same. When not at work, she likes to spend her time listening to music, reading books and travelling to new places.

Knowledge, attitude and practice (KAP) of parents regarding introduction of a new vaccine in the national immunization schedul.

Please share us below details to Download or View Brochure.
This Field is Mandatory and does not allow numerics
This Field is Mandatory and Valid Email should be entered


Mercure Sydney International Airport,

22 Levey Street, 2205 Wolli Creek,

Sydney, Australia.

Hotel Features:

  • Shuttle bus service to Sydney Airport – via the domestic and international terminals
  • Secure parking (maximum cost of $25 per day)
  • 24-hour reception
  • 100% non-smoking accommodation
  • Express checkout
  • Wi-Fi Internet access (free for all Le Club Accor Hotels Loyalty members)
  • Wake-up call service
  • Mercure Pillow Menu
  • Dry cleaning and same day laundry service
  • Safety deposit boxes
  • 24-hour in-room dining
  • Go-Get Car share with two vehicles onsite
  • Seasons Restaurant & Bar

Sydney, capital of New South Wales and one of Australia's largest cities, is best known for its harbourfront Sydney Opera House, with a distinctive sail-like design. Massive Darling Harbour and the smaller Circular Quay port are hubs of waterside life, with the arched Harbour Bridge and esteemed Royal Botanic Garden nearby. Sydney Tower’s outdoor platform, the Skywalk, offers 360-degree views of the city and suburbs.

Terms & Conditions

Requesting an Invitation Letter:

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact to request a personalized letter of invitation.

All cancellations or modifications of registration must be made in writing to

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Innovate Conferences will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Innovate Conferences, including the inability to obtain a visa.

Privacy Policy

Innovate Conferences are committed to safeguarding the privacy of the users of the Innovate Conferences website, while providing an accommodation which is tailored to suit their desiderata. Please take a moment to read our Privacy Policy as it describes what transpires to the personal information which you supply to Innovate Conferences. Innovate Conferences reserves the right to transmute the terms of this Privacy Policy from time to time

Refund Policy:

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund arrangements apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep Refund Policy is as following slabs-

Refunds will be done within 30 days from the day of registration: Eligible for 70% of payment Refund

Accommodation Cancellation Policy:

Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation.

Cancellation Policy:

If Innovate Conferences cancels this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Innovate Conferences which must occur within one year from the date of cancellation.


If Innovate Conferences postpones an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Innovate Conferences event which must occur within one year from the date of postponement.

Transfer of registration

All fully paid registrations are transferable to other persons from the same organization, if registered person is unable to attend the event. Transfers must be made by the registered person in writing to Details must be included the full name of replacement person, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Innovate Conferences if the person is unable to attend one of conferences.

Important Note

Registration prices will be vary based on early bird dates and Innovate Conferences has the whole rights to cancel the registration at any time & no one is subjected to take/record the photographs & videos of events. Participants do not have any rights to disturb the events by miscommunication, by objecting, in any other ways, in such cases the respected person/s will not be permitted / allowed to access the event even though if he/she registered, Innovate Conferences holds the whole rights in this

What information does Innovate Conferences hold about you and how is it amassed?

If you register on the Innovate Conferences Sites, your personal information (including your designation, job designation, company's denomination, telephone, fax and mobile numbers, postal and electronic mail address) is amassed by Innovate Conferences. We withal accumulate personal information from you when you contact us by email or otherwise.

In prevalence with many other websites and online accommodations, we may use "cookies" to store and sometimes track information about you, such as your Internet Protocol (IP) address, but only on an incognito substructure. None of the information we store via cookies is linked to personally identifiable information (PPI). A cookie is a scintilla of data sent from the server which is stored on your PC's hard drive. You can set your browser to reluctant cookies or ask your browser to show you where cookies have been set up. Certain accommodations are only activated by the presence of a cookie and, if you opt to abnegate the cookie, a particular on-line feature may not be available to you

What does Innovate Conferences do with your personal information?

All of the personal information described above will be stored on Innovate Conferences utilizer database (unless you notify us that you no longer wish us to retain such information, in which case it will be effaced). Innovate Conferences will only utilize your personal information in order to contact you (for example by email, mail or telephone) for those purposes to which you have previously consented on the site. For example, if you register on the site, if you submit abstract on the site, Innovate Conferences will email to you Innovate Conferences newsletter and, if you wish, contact you about relevant products and services offered by Innovate Conferences or by reputable third parties. If you do not wish to receive information about Innovate Conferences and/or third parties' products and services, you may send an email to with the subject line unsubscribe and do share the reason.

Innovate Conferences may use Google Analytics for the following purposes:

  • Remarketing (serving ads on 3rd party websites). Innovate Conferences and 3rd-party vendors, including Google, use cookies to serve and target ads based on past visits and interactions with our website.
  • Google Display Network Impression Reporting. Innovate Conferences and 3rd-party vendors use cookies to understand and report on how ad impressions, interactions with ads and other ad services are related to visits to our website.
  • Google Analytics Demographics and Interest Reporting. Innovate Conferences use information from Google's Interest-based advertising or 3rd-party audience data (such as gender, age and interests) with Google Analytics to influence our marketing strategy. Personal information is not captured unless expressly provided by the user. You may opt out of the Google Analytics Display by sending an email to

To whom is your personal information disclosed?

Innovate Conferences will apportion your personal information with the other members of its group (until if you unsubscribe) will make your denomination and postal address available to reputable third parties so that they can send you details of their products and accommodations. In supplying Innovate Conferences with your personal information, you accede that Innovate Conferences may transfer that information (to the extent that it is still held on our database at the pertinent time) to a third party who acquires all or substantially all or Innovate Conferences assets or stock or our website accommodations whether by merger, acquisition, re-organization or otherwise. Innovate Conferences will not otherwise disclose your personal information to any third parties.

Transfers of personal information overseas

As the cyber world is an ecumenical environment, utilizing the cyber world to amass and process personal information indispensably involves the transmission of that information ecumenical. Innovate Conferences will additionally share your personal information with members of its group which are located overseas. By registering on the Innovate Conferences site and communicating with us, you acknowledge and accede to our processing of your personal information in this way.

When does this Privacy Policy not apply?

This Privacy Policy only applies to the amassment and utilization of data by Innovate Conferences. It does not cover third party sites to which we provide links. Those sites may have their own privacy policies. If you send to us contributions containing personal information to be posted on the Innovate Conferences sites, this information will be publicly accessible and is not covered by this Privacy policy.

How do we forfend your information?

Innovate Conferences is committed to data security. If you subscribe to access our premium content (and, accordingly, enter payment details), Innovate Conferences offers the utilization of a secure server. The secure server software encrypts all information which you input afore it is sent to Innovate Conferences. Innovate Conferences takes steps to sentinel against unauthorized access to the personal information of the users of its site. Albeit it makes every effort to engender a secure environment for your personal information, Innovate Conferences cannot guarantee the safety of any personal information which is transmitted to us online.

Contact us

If you have any questions or concerns about Innovate Conferences use of your personal information, please email at we will assist you within 10 working days

Scroll To Top